Jazz Pharmaceuticals acquires Redx’s KRAS inhibitor program
Alderley Park, UK: Jazz Pharmaceuticals plc and Redx Pharma plc have signed a definitive agreement under which Jazz will acquire Redx’s KRAS (Kirsten rat sarcoma virus) inhibitor program. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities. “KRAS is a…